Clinical Trial Update: A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States [Phase 3]

View source ↗

Summary

A continuation Phase 3 trial update for subjects with systemic lupus erythematosus who completed protocol HGS1006-C1056 in the United States; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• HGS1006

Snippet

Sponsor: Human Genome Sciences Inc., a GSK Company | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2016-03-28